Abstract
Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.
| Original language | English |
|---|---|
| Pages (from-to) | 711-717 |
| Number of pages | 7 |
| Journal | Protein and Cell |
| Volume | 1 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- diagnostic biomarker
- LMP2
- uterine leiomyoma
- uterine leiomyosarcoma
ASJC Scopus subject areas
- Biotechnology
- Cell Biology
- Drug Discovery
- Biochemistry
Cite this
Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. / Hayashi, Takuma; Horiuchi, Akiko; Sano, Kenji; Hiraoka, Nobuyoshi; Kanai, Yae; Shiozawa, Tanri; Tonegawa, Susumu; Konishi, Ikuo.
In: Protein and Cell, Vol. 1, No. 8, 2010, p. 711-717.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma
AU - Hayashi, Takuma
AU - Horiuchi, Akiko
AU - Sano, Kenji
AU - Hiraoka, Nobuyoshi
AU - Kanai, Yae
AU - Shiozawa, Tanri
AU - Tonegawa, Susumu
AU - Konishi, Ikuo
PY - 2010
Y1 - 2010
N2 - Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.
AB - Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.
KW - diagnostic biomarker
KW - LMP2
KW - uterine leiomyoma
KW - uterine leiomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=79953158757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953158757&partnerID=8YFLogxK
U2 - 10.1007/s13238-010-0095-x
DO - 10.1007/s13238-010-0095-x
M3 - Review article
VL - 1
SP - 711
EP - 717
JO - Protein and Cell
JF - Protein and Cell
SN - 1674-800X
IS - 8
ER -